A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of the study is to test a new investigational compound called FPA008, in combination with another study drug called nivolumab.
Description
The purpose of this study is to test a new investigational compound called FPA008, in combination with another study drug called nivolumab.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Advanced Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
19 Apr 2024.
Study ID: 1510571033 (FPA008-003)
